JHU-UMD Diabetes Research Center

约翰霍普金斯大学-马里兰大学糖尿病研究中心

• 批准号: 9221319
• 负责人: REXFORD S. AHIMA
• 金额: $ 194.28万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-01 至 2019-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9221319
• 关键词: Affect; Appointment; Basic Science; Biomedical Research; Childhood; Clinical; Clinical Research; Collaborations; Diabetes Mellitus; Diagnosis; Endocrinology; Evaluation; Fostering; Funding; Genetic Research; Healthcare; Historically Black Colleges and Universities; Institution; Insulin-Dependent Diabetes Mellitus; Laboratories; Maryland; Medicine; Minority; Non-Insulin-Dependent Diabetes Mellitus; Persons; Population; Public Health Schools; Research; Research Personnel; Research Training; Resource Sharing; Speed; Translational Research; Translations; Universities; authority; burden of illness; collaborative environment; college; cost effective; interest; medical schools; multidisciplinary; operation; programs; public health relevance

DESCRIPTION (provided by applicant): This proposal seeks continued funding for the JHU-UMD Diabetes Research Center (DRC). The proposed Center will continue to involve investigators from Johns Hopkins University and the University of Maryland. These investigators have primary appointments in numerous departments within and between these Institutions; and while their scientific backgrounds are diverse, they share a common interest in diabetes and endocrinology research and many have established collaborations. The aims of the Center are the following: 1) to foster collaborative, multidisciplinary diabetes and endocrinology research in a supportive environment; 2) to enhance the clinical and basic research capabilities of established diabetes investigators; 3) to encourage investigators not involved in diabetes research to become interested in pursuing problems related to diabetes and endocrinology; 4) to develop, implement and evaluate programs that deliver cost effective health care for the treatment of persons with diabetes; 5) to speed the translation of advances in basic biomedical and genetic research to the clinical arena where they may be applied to the diagnosis and treatment of persons with diabetes; and 6) to inform others in both professional and lay settings of the accomplishments, opportunities and advancements in diabetes research and training. This application contains six separate components: Administrative, Biomedical Research, Pilot and Feasibility, Enrichment, a Regional Shared Resource core, and a Shared Research Core and expansion of the P&F program to a Historically Black University, Howard University College of Medicine. The Administrative Component will be responsible for overseeing the operation of the Center as a whole. The Biomedical Research Component will consist of five Core Laboratories to foster collaborative diabetes research. A Pilot and Feasibility Component will foster the participation and interaction of junior investigators with established investigators in research' related to diabetes. The Enrichment Program will facilitate the interaction within and between Johns Hopkins University and the University of Maryland.

描述(由申请人提供)：该提案寻求继续为JHU-UMD糖尿病研究中心(DRC)提供资金。拟议中的中心将继续有来自约翰·霍普金斯大学和马里兰大学的调查人员参与。这些研究人员在这些机构内部和之间的许多部门有初步任命；虽然他们的科学背景不同，但他们在糖尿病和内分泌学研究方面有着共同的兴趣，许多人已经建立了合作关系。该中心的目标如下：1)在支持性环境中促进协作、多学科的糖尿病和内分泌学研究；2)提高现有糖尿病研究人员的临床和基础研究能力；3)鼓励不参与糖尿病研究的研究人员有兴趣研究与糖尿病和内分泌学有关的问题；4)开发、实施和评估为糖尿病患者的治疗提供成本效益的医疗保健的计划；5)加快将基础生物医学和基因研究的进展转化为临床领域，以便将其应用于糖尿病患者的诊断和治疗；以及6)向其他专业和非专业人员通报糖尿病研究和培训方面的成就、机会和进展。该应用程序包含六个独立的组成部分：管理、生物医学研究、试点和可行性、丰富、区域共享资源核心和共享研究核心以及将P&F项目扩展到历史悠久的黑人大学--霍华德大学医学院。行政部门将负责监督整个中心的运作。生物医学研究部分将由五个核心实验室组成，以促进合作的糖尿病研究。试点和可行性部分将促进初级研究人员与现有研究人员在与糖尿病相关的研究中的参与和互动。丰富计划将促进约翰霍普金斯大学和马里兰大学内部和之间的互动。

项目成果

From fat fruit fly to human obesity.

• DOI: 10.1016/j.physbeh.2014.01.017
• 发表时间: 2014-09
• 期刊: Physiology & behavior
• 影响因子: 2.9
• 作者: Smith WW;Thomas J;Liu J;Li T;Moran TH
• 通讯作者: Moran TH

The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes.

• DOI: 10.3389/fimmu.2012.00196
• 发表时间: 2012
• 期刊: Frontiers in immunology
• 影响因子: 7.3
• 作者: Hamad AR;Arcara K;Uddin S;Donner T
• 通讯作者: Donner T

NH2-terminal pro-brain natriuretic peptide and risk of diabetes.

• DOI: 10.2337/db13-0478
• 发表时间: 2013-09
• 期刊: Diabetes
• 影响因子: 7.7
• 作者: Lazo M;Young JH;Brancati FL;Coresh J;Whelton S;Ndumele CE;Hoogeveen R;Ballantyne CM;Selvin E
• 通讯作者: Selvin E

Modeling Inpatient Glucose Management Programs on Hospital Infection Control Programs: An Infrastructural Model of Excellence.

根据医院感染控制计划对住院患者血糖管理计划进行建模：卓越的基础设施模型。

• DOI: 10.1016/s1553-7250(15)41043-8
• 发表时间: 2015
• 期刊: Joint Commission journal on quality and patient safety
• 影响因子: 2.3
• 作者: Mathioudakis,Nestoras;Pronovost,PeterJ;Cosgrove,SaraE;Hager,Daniel;Golden,SheritaHill
• 通讯作者: Golden,SheritaHill

Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.

Empagliflozin 是一种钠葡萄糖协同转运蛋白 2 抑制剂，用于治疗 1 型糖尿病。

• DOI: 10.1517/13543784.2014.909407
• 发表时间: 2014
• 期刊: Expert opinion on investigational drugs
• 影响因子: 6.1
• 作者: Lamos,ElizabethM;Younk,LisaM;Davis,StephenN
• 通讯作者: Davis,StephenN